Last reviewed · How we verify
Pulsatile Gonadotropin Releasing Hormone
At a glance
| Generic name | Pulsatile Gonadotropin Releasing Hormone |
|---|---|
| Also known as | Pulsatile GnRH pump |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism (PHASE2)
- Kisspeptin Administration Subcutaneously to Patients With IHH (PHASE2)
- GnRH Therapy on Cognition in Down Syndrome (PHASE2, PHASE3)
- Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS) (PHASE1)
- Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism (PHASE1)
- LutrePulse Hypogonadotropic Hypogonadism (PHASE3)
- Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary Syndrome (PHASE4)
- Pulsatile GnRH in Anovulatory Infertility (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: